Literature DB >> 11208528

Troponin I chimera analysis of the cardiac myofilament tension response to protein kinase A.

M V Westfall1, I Turner, F P Albayya, J M Metzger.   

Abstract

Viral-mediated gene transfer of troponin I (TnI) isoforms and chimeras into adult rat cardiac myocytes was used to investigate the role TnI domains play in the myofilament tension response to protein kinase A (PKA). In myocytes expressing endogenous cardiac TnI (cTnI), PKA phosphorylated TnI and myosin-binding protein C and decreased the Ca2+ sensitivity of myofilament tension. In marked contrast, PKA did not influence Ca2+-activated tension in myocytes expressing the slow skeletal isoform of TnI or a chimera (N-slow/card-C TnI), which lack the unique phosphorylatable amino terminal extension found in cTnI. PKA-mediated phosphorylation of a second TnI chimera, N-card/slow-C TnI, which has the amino terminal region of cTnI, caused a decrease in the Ca2+ sensitivity of tension comparable in magnitude to control myocytes. Based on these results, we propose the amino terminal region shared by cTnI and N-card/slow-C TnI plays a central role in determining the magnitude of the PKA-mediated shift in myofilament Ca2+ sensitivity, independent of the isoform-specific functional domains previously defined within the carboxyl terminal backbone of TnI. Interestingly, exposure of permeabilized myocytes to acidic pH after PKA-mediated phosphorylation of cTnI resulted in an additive decrease in myofilament Ca2+ sensitivity. The isoform-specific, pH-sensitive region within TnI lies in the carboxyl terminus of TnI, and the additive response provides further evidence for the presence of a separate domain that directly transduces the PKA phosphorylation signal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208528     DOI: 10.1152/ajpcell.2001.280.2.C324

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  Molecular determinants of cardiac myocyte performance as conferred by isoform-specific TnI residues.

Authors:  Brian R Thompson; Evelyne M Houang; Yuk Y Sham; Joseph M Metzger
Journal:  Biophys J       Date:  2014-05-20       Impact factor: 4.033

2.  Advancing physiological maturation in human induced pluripotent stem cell-derived cardiac muscle by gene editing an inducible adult troponin isoform switch.

Authors:  Matthew Wheelwright; Jennifer Mikkila; Fikru B Bedada; Mohammad A Mandegar; Brian R Thompson; Joseph M Metzger
Journal:  Stem Cells       Date:  2020-06-16       Impact factor: 6.277

3.  Expression of slow skeletal troponin I in adult transgenic mouse heart muscle reduces the force decline observed during acidic conditions.

Authors:  B M Wolska; K Vijayan; G M Arteaga; J P Konhilas; R M Phillips; R Kim; T Naya; J M Leiden; A F Martin; P P de Tombe; R J Solaro
Journal:  J Physiol       Date:  2001-11-01       Impact factor: 5.182

4.  Structure-activity studies of RFamide-related peptide-1 identify a functional receptor antagonist and novel cardiac myocyte signaling pathway involved in contractile performance.

Authors:  Ruthann Nichols; Chloe Bass; Leslie Demers; Brian Larsen; Elton Li; Nathan Blewett; Kimber Converso-Baran; Mark W Russell; Margaret V Westfall
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

5.  Myocardial Mycn is essential for mouse ventricular wall morphogenesis.

Authors:  Cristina Harmelink; Yin Peng; Paige DeBenedittis; Hanying Chen; Weinian Shou; Kai Jiao
Journal:  Dev Biol       Date:  2012-10-12       Impact factor: 3.582

6.  Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants.

Authors:  Jennifer Davis; Haitao Wen; Terri Edwards; Joseph M Metzger
Journal:  J Mol Cell Cardiol       Date:  2008-02-26       Impact factor: 5.000

Review 7.  Tuning cardiac performance in ischemic heart disease and failure by modulating myofilament function.

Authors:  Sharlene M Day; Margaret V Westfall; Joseph M Metzger
Journal:  J Mol Med (Berl)       Date:  2007-03-30       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.